← Issue №17/ week of Oct 25, 2026/Pancreas/Biliary

Redefining Cholangiocarcinoma Management: Breakthroughs and Their Clinical Implications for Clinical Practice.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary review · Oct 21, 2026 · Clin Gastro Hep · IF 16.2

Redefining Cholangiocarcinoma Management: Breakthroughs and Their Clinical Implications for Clinical Practice.

New evidencecholangiocarcinomabiomarkertranslationalguideline
Clinical takeawayMolecular profiling identifies candidates for biomarker-driven therapy, and immunotherapy has been integrated into first-line treatment; early detection and risk stratification remain the main gaps.
What it foundRecent advancements in imaging and next-generation sequencing (NGS) have improved diagnostic accuracy and identified actionable molecular alterations (e.g., FGFR2 fusions, IDH1 mutations) in cholangiocarcinoma.
ContextThis review highlights advancements in precision medicine for cholangiocarcinoma, particularly in unresectable or metastatic cases, emphasizing the role of molecular profiling and immunotherapy.
Emergingsuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Kodali S … Ghobrial RM · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues